A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas

被引：0
|
作者：
Stéphane Goutagny
Marco Giovannini
Michel Kalamarides
机构：
[1] Assistance Publique Hôpitaux de Paris,Neurochirurgie
[2] Hôpital Beaujon,undefined
[3] Hôpital Pitié Salpêtrière,undefined
[4] Assistance Publique Hôpitaux de Paris,undefined
[5] University of California Los Angeles,undefined
来源：
Journal of Neuro-Oncology | 2017年 / 133卷
关键词：
Bevacizumab; Meningioma; Everolimus; Rebound Effect; Vestibular Schwannoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：443 / 445
页数：2
相关论文
共 50 条
  • [31] A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor
    Chan, Jennifer A.
    Blaszkowsky, Lawrence
    Stuart, Keith
    Zhu, Andrew X.
    Allen, Jill
    Wadlow, Raymond
    Ryan, David P.
    Meyerhardt, Jeffrey
    Gonzalez, Marielle
    Regan, Eileen
    Zheng, Hui
    Kulke, Matthew H.
    CANCER, 2013, 119 (17) : 3212 - 3218
  • [32] A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma
    Kim, Dong-Wan
    Oh, Do-Youn
    Shin, Seong Hoon
    Kang, Jin Hyoung
    Cho, Byoung Chul
    Chung, Joo-Seop
    Kim, HyeJin
    Park, Keon Uk
    Kwon, Jung Hye
    Han, Ji-Youn
    Kim, Mi-Jung
    Bang, Yung-Jue
    BMC CANCER, 2014, 14
  • [33] A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma
    Dong-Wan Kim
    Do-Youn Oh
    Seong Hoon Shin
    Jin Hyoung Kang
    Byoung Chul Cho
    Joo-Seop Chung
    HyeJin Kim
    Keon Uk Park
    Jung Hye Kwon
    Ji-Youn Han
    Mi-Jung Kim
    Yung-Jue Bang
    BMC Cancer, 14
  • [34] Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
    Kordes, S.
    Klumpen, H. J.
    Weterman, M. J.
    Schellens, J. H. M.
    Richel, D. J.
    Wilmink, J. W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1135 - 1141
  • [35] Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
    S. Kordes
    H. J. Klümpen
    M. J. Weterman
    J. H. M. Schellens
    D. J. Richel
    J. W. Wilmink
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1135 - 1141
  • [36] Imatinib and Everolimus in Patients With Progressing Advanced Chordoma: A Phase 2 Clinical Study
    Stacchiotti, Silvia
    Morosi, Carlo
    Lo Vullo, Salvatore
    Casale, Alessandra
    Palassini, Elena
    Frezza, Anna Maria
    Dinoi, Gabriella
    Messina, Antonella
    Gronchi, Alessandro
    Cavalleri, Adalberto
    Venturelli, Elisabetta
    Morelli, Daniele
    Pilotti, Silvana
    Collini, Paola
    Brich, Silvia
    Tamborini, Elena
    Mariani, Luigi
    Casali, Paolo G.
    CANCER, 2018, 124 (20) : 4056 - 4063
  • [37] RETRACTED ARTICLE: A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients
    Jun Yao
    Jian-yao Wang
    Yi Liu
    Bin Wang
    Ying-xue Li
    Ru Zhang
    Li-Sheng Wang
    Lei Liu
    Medical Oncology, 2014, 31
  • [38] Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study
    Nicolai Maass
    Nadia Harbeck
    Christoph Mundhenke
    Christian Lerchenmüller
    Jana Barinoff
    Hans-Joachim Lück
    Johannes Ettl
    Bahriye Aktas
    Sherko Kümmel
    Siegfried Rösel
    Steffen Wagner
    Lothar Müller
    Joachim Bischoff
    Kristina Lübbe
    Kathrin Schwedler
    Marcus Schmidt
    Dirk Bauerschlag
    Valentina Nekljudova
    Gunter von Minckwitz
    Sibylle Loibl
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 2047 - 2056
  • [39] Phase 2 study of cisplatin and everolimus in patients with metastatic extrapulmonary neuroendocrine carcinoma (NEC)
    Levy, S.
    Verbeek, W.
    Eskens, F.
    de Groot, D. J.
    Van Leerdam, M.
    Tesselaar, M.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 140 - 140
  • [40] Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study
    Maass, Nicolai
    Harbeck, Nadia
    Mundhenke, Christoph
    Lerchenmueller, Christian
    Barinoff, Jana
    Lueck, Hans-Joachim
    Ettl, Johannes
    Aktas, Bahriye
    Kuemmel, Sherko
    Roesel, Siegfried
    Wagner, Steffen
    Mueller, Lothar
    Bischoff, Joachim
    Luebbe, Kristina
    Schwedler, Kathrin
    Schmidt, Marcus
    Bauerschlag, Dirk
    Nekljudova, Valentina
    von Minckwitz, Gunter
    Loibl, Sibylle
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (12) : 2047 - 2056
12345